100 Participants Needed

Community Support Program for Lung Cancer Screening

(LCS II Trial)

FD
CR
Overseen ByCaroline Rosen
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Abramson Cancer Center at Penn Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This is a West Philadelphia based community project to improve adherence to lung cancer screening. The overall objective of this project is to demonstrate the impact of a community support program (CSP) on improve adherence to LCS follow-up guidelines in an urban environment. The study will target individuals in the Penn Medicine healthcare system residing in Philadelphia with an upcoming or missed follow-up screening or orders placed but who have not yet scheduled their screenings by offering free transportation coordination to and from the appointment. The study team will also offer to connect those with placed but unscheduled low dose CT orders to connect with Penn Medicine's scheduling staff.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Scheduling, Transportation in the Community Support Program for Lung Cancer Screening?

Research shows that patient navigation, which includes scheduling and transportation support, improves lung cancer screening rates among underserved populations. This suggests that similar support services can help increase access to lung cancer screening, potentially improving early detection and survival rates.12345

Is the Community Support Program for Lung Cancer Screening safe for humans?

The research articles provided do not contain specific safety data for the Community Support Program for Lung Cancer Screening or related interventions like Scheduling and Transportation. They focus on the effectiveness and barriers of lung cancer screening programs, but do not address safety concerns.46789

How does the Community Support Program for Lung Cancer Screening differ from other treatments?

The Community Support Program for Lung Cancer Screening is unique because it uses a Community Health Worker (CHW) model to increase lung cancer screening rates, particularly among underserved groups like Chinese immigrant drivers. This approach is culturally tailored and focuses on education and support, which is different from traditional medical treatments that focus solely on medical procedures or medications.210111213

Research Team

FD

Farouk Dako, MD

Principal Investigator

farouk.dako@pennmedicine.upenn.edu

Eligibility Criteria

This trial is for individuals in Philadelphia who are due or have missed their low dose CT scan for lung cancer screening. Participants must be part of the Penn Medicine healthcare system and will receive help with transport and scheduling.

Inclusion Criteria

I am due for or missed my low dose CT scan for lung cancer.
I live in Philadelphia.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Community Support Program Implementation

Participants receive support through transportation coordination and scheduling assistance to improve adherence to lung cancer screening follow-up

6 months

Follow-up

Participants are monitored for adherence to lung cancer screening follow-up guidelines

6 months

Treatment Details

Interventions

  • Scheduling
  • Transportation
Trial Overview The study tests a community support program (CSP) that provides free transportation and helps schedule screenings to see if it improves adherence to follow-up guidelines for lung cancer screening in an urban setting.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: West PhiladelphiaExperimental Treatment2 Interventions
Eligible patient population lives in West Philadelphia
Group II: Southwest PhiladelphiaActive Control1 Intervention
Eligible patient population lives in Southwest Philadelphia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Abramson Cancer Center at Penn Medicine

Lead Sponsor

Trials
425
Recruited
464,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Findings from Research

In New York state, nearly half (48.3%) of lung cancer patients were diagnosed with late-stage disease, highlighting the need for improved access to lung cancer screening resources, especially in rural areas.
The study found that rural counties had fewer lung cancer screening centers and higher lung cancer mortality rates, indicating that geographic disparities in healthcare resources significantly impact patient outcomes.
A Multilevel Approach to Investigate Relationships Between Healthcare Resources and Lung Cancer.Somayaji, D., Seo, YS., Wilding, GE., et al.[2023]
In British Columbia, the median travel time to lung cancer screening sites was 11.7 minutes, but this increased significantly for patients in rural areas, with 99% of those facing over 60 minutes of travel living in these regions.
The study found that longer drive times to screening sites were linked to various factors such as sex, economic status, and situational vulnerability, indicating that disadvantaged groups may need additional support to access lung cancer screening services.
Addressing Inequity in Spatial Access to Lung Cancer Screening.Simkin, J., Khoo, E., Darvishian, M., et al.[2023]
Lung cancer screening has been shown to improve survival rates, but many people are not participating in these screenings due to various barriers.
The authors emphasize the importance of creating a tailored and adaptable lung cancer screening program that addresses community needs, involves key stakeholders, and optimizes health systems for better patient follow-up.
Building a Lung Cancer Screening Program.Chudgar, NP., Stiles, BM.[2023]

References

A Multilevel Approach to Investigate Relationships Between Healthcare Resources and Lung Cancer. [2023]
Addressing Inequity in Spatial Access to Lung Cancer Screening. [2023]
Building a Lung Cancer Screening Program. [2023]
Community-Based Multidisciplinary Computed Tomography Screening Program Improves Lung Cancer Survival. [2022]
Patient navigation for lung cancer screening among current smokers in community health centers a randomized controlled trial. [2019]
Addressing Transportation Insecurity Among Patients With Cancer. [2023]
Update on screening for lung cancer. [2023]
Understanding Factors Associated with Uptake of Lung Cancer Screening among Individuals at High Risk. [2023]
Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Chinese Livery Drivers' Perspectives on Adapting a Community Health Worker Intervention to Facilitate Lung Cancer Screening. [2023]
Healthcare Professionals' Perspectives on Adapting a Community Health Worker Model to Facilitate Lung Cancer Screening for Chinese For-Hire Vehicle Drivers. [2023]
Adapting Community Educational Programs During the COVID-19 Pandemic: Comparing the Feasibility and Efficacy of a Lung Cancer Screening Educational Intervention by Mode of Delivery. [2023]
Lung cancer screening program factors that influence psychosocial outcomes: A systematic review. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity